Business Wire

CHRYSO

9.9.2020 15:12:38 CEST | Business Wire | Press release

Share
CHRYSO and SOLIDIA Partner to Deploy Ultra-low CO2 Concrete

CHRYSO, a world leader in construction chemicals, today announces its partnership with Solidia Technologies, a start-up inventor of revolutionary technology for green cement and concrete. The two companies will collaborate to improve the sustainability performance and material properties of Solidia® ultra-low CO2 concrete through their combined chemical expertise.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200909005655/en/

The partnership is underpinned by a long-term commitment from both companies to making sustainable solutions accessible to cement and concrete producers worldwide.
Solidia® sustainable technology is already available in the precast market and used for non-reinforced concrete elements. Solidia’s unique technologies are based on a revolutionary cement chemistry that can be produced at lower energies, significantly lowering carbon emissions, and that does not hydrate but carbonates by injection of CO2 into fresh concrete. Combined, Solidia’s processes lower the carbon footprint of concrete by up to 70%, while reducing water and energy consumption. They also improve the performance and durability of concrete, which are further enhanced with new, sophisticated admixture solution.
CHRYSO draws on a solid knowledge of sustainable building materials. For more than 10 years, the company has been developing admixture solutions that allow the intensive use of alternative binders without compromising material performance.

“The development of innovative admixture solutions adapted to Solidia’s new binder, boosting the final properties of concrete, is one of our R&D works in progress. This will enable higher strengths, an improved finish of the fresh concrete, and the optimization of the curing process. Together with Solidia, we will scale the use of low CO2 concrete, helping manufacturers produce high quality precast elements,” declared Jean Mascaro, Concrete BU director of CHRYSO.

Tom Schuler, president and CEO of Solidia Technologies , said: “Incorporating CHRYSO® ’s exclusive water-reducing admixtures adapted to the specific chemistry of Solidia Concrete™, will further reduce water consumption in the curing process.”
A key objective for the start-up is to improve cement and concrete production and performance while enhancing its environmental impact. Tom Schuler added: “By cutting energy consumption during the curing process, CHRYSO will help us achieve our ambitions and reach higher levels of performance.”

This partnership paves the way for upcoming advances in CO 2 footprint reduction and new developments in sustainable chemistry. The deployment of new ultra-low C0 2 concrete will accelerate the decarbonization of the construction industry.

About the CHRYSO Group
Aimed at cement manufacturers, ready-mix concrete and precast industrials, and construction companies, CHRYSO's offer includes cement additives, concrete admixtures and Solutions for Construction Systems (waterproofing solutions, mortars, etc.). CHRYSO® solutions have won renown on the most prestigious construction sites throughout the world thanks to the group's extensive network, which includes 22 foreign subsidiaries and covers more than 100 countries through its wide network of distributors, licensees and agents. The CHRYSO group employs over 1,300 staff worldwide. Innovation, customer service, expertise and technical know-how are the CHRYSO Group's cornerstones. More info about CHRYSO: www.chryso.com

About Solidia Technolgies
Solidia Technologies® is a cement and concrete technology company that makes it easy and profitable to use CO2 to manufacture superior, sustainable building materials. Each year, Solidia can eliminate at least 1.5 Gt of CO₂, save 3 trillion liters of fresh water, reduce cement industry energy consumption by 67 Mt of coal, and eliminate 100 Mt of concrete waste landfill. Produced using the same raw materials and existing equipment, Solidia products are higher performing and cost less to produce than traditional concrete, and cure in less than 24 hours. Solidia offers a rapid, globally scalable response to one of the greatest threats to our planet.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye